Stock Events

Stock Events

Xeris Biopharma

$5.65

0

+$0+0% Tuesday 01:36

Statistics

Day High

5.65

Day Low

5.65

52W High

-

52W Low

-

Volume

60

Avg. Volume

-

Mkt Cap

937.47M

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

7MayExpected

Q3 2025

Q4 2025

Next

0

0.02

0.04

0.06

Expected EPS

0

Actual EPS

N/A

Financials

-27%Profit Margin

Unprofitable

2021

2022

2023

2024

406.14MRevenue

-109.67MNet Income

Analyst Ratings

9.5Average Price Target

The highest estimate is 10.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.

Buy

100%

Hold

0%

Sell

0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow XERS.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products for diabetes and orphan lung diseases, competing directly with Xeris's inhaled and injectable therapies.

Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care, providing products that compete in the diabetes therapeutic area with Xeris.

Sanofi is a global life sciences company that offers a range of diabetes solutions, including insulin therapies that compete with Xeris's glucagon rescue pen.

Eli Lilly and Company is a global healthcare leader that manufactures medicines for diabetes care, directly competing with Xeris's diabetes management products.

AstraZeneca operates in the biopharmaceutical sector, focusing on the development of new medicines for chronic diseases, including diabetes, thus competing with Xeris.

Merck & Co., Inc. offers innovative health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products, including treatments for diabetes, making it a competitor.

Bristol-Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose portfolio of medicines includes treatments for diabetes and cardiovascular diseases, areas where Xeris also operates.

Pfizer Inc. is a research-based global biopharmaceutical company with a broad range of products in various therapeutic areas, including those competing with Xeris's offerings.

Tandem Diabetes Care

Tandem Diabetes Care, Inc. designs, develops, and commercializes products for people with insulin-dependent diabetes, directly competing with Xeris's diabetes management solutions.

Insulet Corporation is an innovative medical device company focused on making the lives of people with diabetes easier through its Omnipod Insulin Management System, competing in the diabetes care market with Xeris.

About

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Show more...

CEO

ISIN

US98422E1038

Listings

0 Comments

Share your thoughts

FAQ

What is Xeris Biopharma stock price today?▼

The current price of XERS.BOATS is $5.65 USD — it has increased by +0% in the past 24 hours. Watch Xeris Biopharma stock price performance more closely on the chart.

What is Xeris Biopharma stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Xeris Biopharma stocks are traded under the ticker XERS.BOATS.

What is Xeris Biopharma market cap?▼

Today Xeris Biopharma has the market capitalization of 937.47M

When is the next Xeris Biopharma earnings date?▼

Xeris Biopharma is going to release the next earnings report on May 07, 2026.

What were Xeris Biopharma earnings last quarter?▼

XERS.BOATS earnings for the last quarter are 0.06 USD per share, whereas the estimation was 0.02 USD resulting in a +190.98% surprise. The estimated earnings for the next quarter are N/A USD per share.

What is Xeris Biopharma revenue for the last year?▼

Xeris Biopharma revenue for the last year amounts to 406.14M USD.

What is Xeris Biopharma net income for the last year?▼

XERS.BOATS net income for the last year is -109.67M USD.

In which sector is Xeris Biopharma located?▼

Xeris Biopharma operates in the Other sector.

When did Xeris Biopharma complete a stock split?▼

Xeris Biopharma has not had any recent stock splits.